#2). "Lieff Cabraser does not engage in client data-sharing. Action Home. For more information, read Hagens Berman Sobol Shapiro LLP is a class-action litigation firm that seeks to protect the rights of consumers, workers, whistleblowers, investors and others. All other Motions to Dismiss were granted to AbbVie.Next meeting is April 8, 2019 to set schedule for limited discovery.Despite intimations written elsewhere on the internet, the attorney (Alan Levin, MD, JD) representing this one Paulsen lawsuit has verified on 07-11-16 that he "has nothing to do with any class action lawsuit", and reaffirmed this on Terry Paulsen, an ICU RN and avid horsewoman prior to becoming disabled post-lupron, had been one of four plaintiffs in a prior class action lawsuit in which the attorney retired mid-case. If anyone can answer that question, please Women have reported problems with using micro-dose lupron in IVF, and women have reported problems with using daily lupron for a matter of days. #'s") listed below, search |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||Inevitably, future class action lawsuits will be filed.|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||(Zoladex [aka 'goserelin'], another GnRHa manufactured by AstraZeneca was also sued by US gov't for 04-25-12: 'Lupron Settlement Surplus Funds Update' ... 04-24-12: In Re: Lupron Marketing & Sales Practice Litigation (Case No.

Dr. Friedman was not the only one to fabricate so-called "clinical trial" participants, or to alter their medical files.Additionally, medical mistreatment to death and disability persisted on the authority of those who came before Dr. Friedman, with no FDA investigation, despite evidence of other "fabricated" clinical trials presented to Health Canada and the FDA in 1998 and 1999.... serving only the recorded interests of manufacturer, now AbbVie (aka Abbott, Takeda-Abbott, TAP), while fully supplanting patient rights.“...anxiety, personality disorder, memory disorder, delusions" ‡During 1998 - 1999,  Canadian medical and legal investigations revealed that "Delusions" were included in product monographs without any medical basis, an apparent convenience of the manufacturer's, with no medical evidence of same to support TAP's claim.Subsequently, "Delusions" was removed as an adverse effect.Apparently, that was all that was done, causing a 16 year-old case to now be unearthed for the good of millions of victims, and to help enable a basis for a class-action lawsuit on the premise of fraudulent studies acquiring FDA NOCs for Lupron use on women, now ignored in favor of "off-label" use to maintain TAP's cash-cow: Ch-Ching goes your health and your personal safety!TAP has just recently revived "delusions" for use as a powerful tool against those suffering LUPRON, demonstrating, again, the manufacturer's determination to facilitate the persecution of those who complain of adverse reactions.__________________________________________________ "FINDINGS OF SCIENTIFIC MISCONDUCT, NIH GUIDE": Volume 25, Number 15, May 10, 1996‡   "Compendium of Pharmaceuticals and Specialties", pp 974-975Liebe Change.org-Nutzerinnen und -Nutzer, wir setzen auf Change.org Cookies ein, um Ihnen möglichst viele interessante Inhalte anzuzeigen. "Lupron is a known "hazardous drug" according to the NIH and according to NIOSH; and Lupron is a known "reproductive toxicant" and a known "developmental toxicant" - all facts well known to Attorney Levin. It is something It is hoped that a second look at Michele's circumstances can take place, this time with a clinically accurate understanding of the mitigating factors created by lupron's adverse psychological effects. 08-01-11: The FIRST lupron lawsuit to be scheduled for TRIAL - 'Klein v. TAP/Abbott', in Nevada (case listed below) - begins on 08-01-11 with jury selection.